Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

NEAL BREIT

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1558419630
CMS profile
70061
Location
WESTWOOD, NJ

General Payments · PY2018–2024

$14,334.68

  • Reported across 156 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$1,708.50

12 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
IBSA Pharma Inc. $1,484.99 4
Boehringer Ingelheim Pharmaceuticals, Inc. $209.97 7
Lilly USA, LLC $13.54 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $2,848.88 42
PY2019 $6,265.78 51
PY2020 $1,700.00 18
PY2021 $1,097.48 10
PY2022 $376.55 13
PY2023 $337.49 10
PY2024 $1,708.50 12

Payment records · PY2024 (12)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Boehringer Ingelheim Pharmaceuticals, Inc. $14.31 01/03/2024 Food and Beverage Undisputed 01/23/2026 1118057409 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.30 03/01/2024 Food and Beverage Undisputed 01/23/2026 1118057407 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $125.00 04/17/2024 Food and Beverage Undisputed 01/23/2026 1118057413 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.99 04/18/2024 Food and Beverage Undisputed 01/23/2026 1118057405 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.55 08/01/2024 Food and Beverage Undisputed 01/23/2026 1118057401 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.96 09/20/2024 Food and Beverage Undisputed 01/23/2026 1118057403 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.86 11/01/2024 Food and Beverage Undisputed 01/23/2026 1118057411 CMS
IBSA Pharma Inc. $125.00 08/06/2024 Food and Beverage Undisputed 01/23/2026 1142976956 CMS
IBSA Pharma Inc. $1,200.00 08/06/2024 Consulting Fee Undisputed 01/23/2026 1142976958 CMS
IBSA Pharma Inc. $150.00 08/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1142976960 CMS
IBSA Pharma Inc. $9.99 10/23/2024 Food and Beverage Undisputed 01/23/2026 1142974425 CMS
Lilly USA, LLC $13.54 06/06/2024 Food and Beverage Undisputed 01/23/2026 1135176117 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.